PHILIPS COMPONENT COMPACT MONITOR, RELEASE A.04, MODEL #M1275B

K021778 · Philips Medical Systems · DQA · Jul 17, 2002 · Cardiovascular

Device Facts

Record IDK021778
Device NamePHILIPS COMPONENT COMPACT MONITOR, RELEASE A.04, MODEL #M1275B
ApplicantPhilips Medical Systems
Product CodeDQA · Cardiovascular
Decision DateJul 17, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.2700
Device ClassClass 2
AttributesPediatric

Intended Use

For monitoring, recording, and alarming of multiple physiological parameters of adults, pediatrics, and neonates in health care facilities. EASI 12-lead ECG is only for use on adult and pediatric patients. ST Segment monitoring is restricted to adult patients only. The transcutaneous gas measurement (tcp02 / tcpCO2) is restricted to neonatal patients only. Bispectral Index (BIS) monitoring is for use in monitoring the state of the brain by data acquisition of EEG signals in the intensive care unit, operating room, and for clinical research. The Bispectral Index, a processed EEG variable, may be used as an aid in monitoring the effects of certain anesthetic agents.

Device Story

Philips M1275B Component Compact Monitor is a multi-parameter physiological monitor for use in health care facilities by clinicians. Device acquires inputs including ECG, gas concentrations, blood pressure, temperature, EEG, and BIS signals. System processes these inputs to provide real-time monitoring, recording, and alarming of patient status. Modification involves updated software and support for M1021A SvO2, M1027A EEG, and M1034A BIS modules, plus M2385A Application Server integration. Output displayed for healthcare providers to assist in clinical decision-making, including anesthetic management and patient status assessment. Benefits include continuous oversight of critical physiological parameters.

Clinical Evidence

Bench testing only. Verification and validation activities included system-level tests, performance tests, and safety testing based on hazard analysis. Pass/Fail criteria were derived from predicate device specifications.

Technological Characteristics

Multi-parameter physiological monitor; supports modular inputs (SvO2, EEG, BIS). Connectivity includes network and communication systems. Software-based monitoring and alarming. Operates as a component of a larger monitoring system (M2385A Application Server).

Indications for Use

Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of adult, pediatric, and neonatal patients in health care facilities. Specific restrictions: EASI 12-lead ECG for adults/pediatrics; ST segment monitoring for adults; transcutaneous gas (tcpO2/tcpCO2) for neonates; BIS monitoring for brain state/anesthetic effect monitoring in ICU/OR.

Regulatory Classification

Identification

An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K621778 ## JUL 1 7 2002 510(k) Summary 9.0 This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 CFR §807.92. 1. The submitter of this premarket notification is: Dave Osborn Quality Program Manager Philips Medical Systems 3000 Minuteman Road Andover, MA 01810-1085 978 659 3178 Tel: Fax: 978 685 5624 Email: dosborn@hsgmed.com This summary was prepared on 29 May, 2002 - 2. The name of this device is the Philips Medical Systems, M1275B Component Compact Monitor. Classification names are as follows: | Device Panel | Classification | ProCode | Description | |-----------------------------------------------------------------------|----------------|---------|-------------------------------------------------------------------------------| | Anesthesiology<br>and Respiratory<br>Therapy Devices<br>Panel (12624) | 868.1400, II | CCK | Analyzer, Gas, Carbon-<br>Dioxide, Gaseous-Phase | | | 868.1500, II | CBQ | Analyzer, Gas, Enflurane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | 868.1500, II | NHO | Analyzer, Gas, Desflurane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | 868.1500, II | NHP | Analyzer, Gas,<br>Sevoflurane, Gaseous-Phase<br>(Anesthetic Concentration) | | | 868.1500, II | NHQ | Analyzer, Gas, Isoflurane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | 868.1620, II | CBS | Analyzer, Gas, Halothane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | 868.1700, II | CBR | Analyzer, Gas, Nitrous-<br>Oxide, Gaseous Phase<br>(Anesthetic Concentration) | | | 868.1720, II | CCL | Analyzer, Gas, Oxygen,<br>Gaseous-Phase | | | 868.2375, II | BZQ | Monitor, Breathing<br>Frequency | | | 868.2480, II | LKD | Monitor, Carbon-Dioxide,<br>Cutaneous | | | 868.2500, II | KLK | Monitor, Oxygen,<br>Cutaneous, for Infant not<br>under Gas Anesthesia | | Circulatory<br>System Devices<br>Panel (12625) | 870.1025, III | DSI | Detector and Alarm,<br>Arrhythmia | | | 870.1025, III | MLD | Monitor, ST Segment with<br>Alarm | | | 870.1025, III | MHX | Monitor, Physiological,<br>Patient (with arrhythmia<br>Detection or alarms) | | | 870.1100, II | DSJ | Alarm, Blood-Pressure | | | 870.1110, II | DSK | Computer, Blood-Pressure | {1}------------------------------------------------ | Device Panel | Classification | ProCode | Description | |---------------------------------------------------------------------|----------------|---------|----------------------------------------------------------------| | | 870.1130, II | DXN | System, Measurement,<br>Blood-Pressure, Non-<br>Invasive | | | 870.1435, II | DXG | Computer, Diagnostic, Pre-<br>Programmed, Single-<br>Function | | | 870.1915, II | KRB | Probe, Thermodilution | | | 870.2060, II | DRQ | Amplifier and Signal<br>Conditioner, Transducer<br>Signal | | | 870.2300, II | DRT | Monitor, Cardiac (incl.<br>Cardiotachometer & Rate<br>Alarm) | | | 870.2340, II | DPS | Electrocardiograph | | | 870.2340, II | MLC | Monitor, ST Segment | | | 870.2370, II | KRC | Tester, Electrode,<br>Surface,<br>Electrocardiograph | | | 870.2450, II | DXJ | Display, Cathode-Ray Tube,<br>Medical | | | 870.2600, I | DRJ | System, Signal Isolation | | | 870.2700, II | DQA | Oximeter | | | 870.2770, II | DSB | Plethysmograph, Impedance | | | 870.2800, II | DSH | Recorder, Magnetic Tape,<br>Medical | | | 870.2810, I | DSF | Recorder, Paper Chart | | | | MSX | System,Network and<br>Communication,<br>Physiological Monitors | | General<br>Hospital and<br>Personal Use<br>Devices Panel<br>(12520) | 880.2910, II | FLL | Thermometer, electronic,<br>clinical | | Neurological<br>Devices Panel<br>(12513) | 882.1400, II | GWR | Electroencephalograph | | Neurological<br>Devices Panel<br>(12513) | 882.1420, I | GWS | Analyzer, Spectrum,<br>Electroencephalogram<br>Signal | - 3. The new device is substantially equivalent to the previously cleared Philips Component Compact Monitor (M1275B) device marketed pursuant to K013199, K020531, and K021300, the Philips Component Monitoring System marketed pursuant to K990125 with the Philips M1021A SvO2 Module marketed pursuant to K942843, the Philips M1027A EEG Module marketed pursuant to K992674, the Philips M1034A BIS Module marketed pursuant to K003038, and the Philips M2391A PC Client marketed pursuant to K021422. - The modification is updated software and the ability to support এ . to the Philips M1021A SvO2 Module, M1027A EEG Module, and M1034A BIS Module as well as the M2385A Application Server. - 5. The new device has the same Indications for Use, for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients, as the legally marketed predicate device. {2}------------------------------------------------ - The new device has the same technological characteristics as the 6. legally marketed predicate device. - 7. Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the new device with respect to the predicate. Testing involved system level tests, performance tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate device and test results showed substantial equivalence. The results demonstrate that Component Compact Monitor meets all reliability requirements and performance claims. {3}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of an eagle with three lines representing its wings and a wavy line representing its body. JUL 1 7 2002 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Dave Osborn Philips Medical Systems 3000 Minuteman Road Andover, Massachusetts 01810 Re: K021778 Philips Component Compact Monitor, Release A.04, M1275B Regulation Number: 870.2700, 882.1400, 870.1025 Regulation Name: Oximeter, Electroencephalograph, and Arrhythmia Detector and Alarm Regulatory Class: III Product Code: DQA, GWQ, and MHX Dated: May 29, 2002 Received: May 30, 2002 Dear Mr. Osborn: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. {4}------------------------------------------------ Page 2 - Mr. Dave Osborn You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours Timothy A. Ulatowski Timo Ulatowski Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ Page ______ of _______________________________________________________________________________________________________________________________________________________________ 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ Device Name: Philips Medical Systems, M1275B Component Compact Monitor, Release A.04, with M1021A SvO2 Module, M1027A EEG Module, and M1034A BIS Module. Indications for Use: Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters patients. Intended use: For monitoring, recording, and alarming of multiple physiological parameters of adults, pediatrics, and neonates in health care facilities. EASI 12-lead ECG is only for use on adult and pediatric patients. ST Segment monitoring is restricted to adult patients only. The transcutaneous gas measurement (tcp02 / tcpCO2) is restricted to neonatal patients only. Bispectral Index (BIS) monitoring is for use in monitoring the state of the brain by data acquisition of EEG signals in the intensive care unit, operating room, and for clinical research. The Bispectral Index, a processed EEG variable, may be used as an aid in monitoring the effects of certain anesthetic agents*. * Gan TJ, Slass P, Windsor A, Payne F, Rosow C, Sebel P, Manberg Bispectral Index Monitoring Allows Faster emergence and P. Improved Recovery from Propofol, Alfentanil, and Nitrous Oxide Anesthesia. Anesthesiology October 1997; (4) 87:808-15. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use V Use (Per 21 CFR 801.109) OR Over-The-C (Division Sign-Off) Division of Dental, Infection Control. and General Hospital Device !- 10(k) Number
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%